In a case series of eight pediatric patients with treatment-resistant autoimmune diseases such as systemic lupus erythematosus, dermatomyositis, or systemic sclerosis, autologous anti-CD19 CAR T cell therapy was applied. This therapy has been shown to be feasible. She was safe. It was effective in reducing disease activity. The study was published in Nature Medicine on February 5, 2026.